Holen Sie sich die Stockscreener-App
1.11
2.78%
0.03
Schlusskurs vom Vortag:
$1.08
Offen:
$1.12
24-Stunden-Volumen:
128.31K
Relative Volume:
0.09
Marktkapitalisierung:
$29.18M
Einnahmen:
$1.79M
Nettoeinkommen (Verlust:
$-70.90M
KGV:
-0.0714
EPS:
-15.54
Netto-Cashflow:
$-34.95M
1W Leistung:
+0.91%
1M Leistung:
-27.92%
6M Leistung:
-52.77%
1J Leistung:
-71.54%
1-Tages-Spanne:
$1.10
$1.16
1-Wochen-Bereich:
$1.08
$1.18
52-Wochen-Spanne:
$1.04
$5.10
Senti Biosciences Inc Stock (SNTI) Company Profile
Firmenname
Senti Biosciences Inc
Sektor
Branche
Telefon
(650) 239-2030
Adresse
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Vergleichen Sie SNTI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
1.11 | 28.39M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.67 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.37 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
813.75 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.69 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-06 | Eingeleitet | Laidlaw | Buy |
| 2022-10-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Aktie (SNTI) Neueste Nachrichten
Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference - The Manila Times
Will Senti Biosciences Inc. stock outperform value stocksRisk Management & AI Forecasted Stock Moves - ulpravda.ru
Why Senti Biosciences Inc. stock is a value investor pick2025 Sector Review & Free Daily Entry Point Trade Alerts - ulpravda.ru
Why Senti Biosciences Inc. stock remains on buy listsM&A Rumor & Growth Focused Investment Plans - ulpravda.ru
Why Senti Biosciences Inc. stock is rated strong buyMarket Sentiment Review & Entry Point Strategy Guides - ulpravda.ru
Can Senti Biosciences Inc. stock beat market expectations this quarterTrade Analysis Report & Weekly Watchlist of Top Performers - ulpravda.ru
Senti Biosciences Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Promising Biotech Stocks To Keep An Eye OnDecember 9th - MarketBeat
Guidance Update: Is Senti Biosciences Inc stock a good choice for value investorsAnalyst Downgrade & Free Verified High Yield Trade Plans - moha.gov.vn
Senti Biosciences, Inc. (SNTI) Stock: Faces Decline Despite Groundbreaking FDA Designation - parameter.io
How sustainable is Senti Biosciences Inc. stock dividend payoutEarnings Miss & High Yield Equity Trading Tips - Улправда
Comparing Longeveron (NASDAQ:LGVN) & Senti Biosciences (NASDAQ:SNTI) - Defense World
Will Senti Biosciences Inc. stock deliver strong dividend growthChart Signals & Growth Focused Stock Pick Reports - ulpravda.ru
Is Senti Biosciences Inc. stock a good choice for value investors2025 Macro Impact & Weekly High Return Stock Forecasts - Bölüm Sonu Canavarı
Income Plays: How institutional buying supports Senti Biosciences Inc. stock2025 Earnings Impact & Real-Time Volume Analysis - Улправда
Why retail investors pile into Senti Biosciences Inc. stock2025 Sector Review & Real-Time Volume Triggers - DonanımHaber
Senti Biosciences Announces New Employment Inducement Grants - The Manila Times
Does Senti Biosciences Inc. stock trade at a discount to peersMarket Movement Recap & Safe Capital Growth Plans - Улправда
Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Senti Biosciences Earnings Notes - Trefis
Senti Biosciences (NASDAQ:SNTI) Rating Increased to Sell at Wall Street Zen - Defense World
Promising Biotech Stocks To Keep An Eye On – December 9th - Defense World
Senti Bio Wins FDA RMAT Designation for SENTI-202 on 50% Response Rate in Leukemia Trial - geneonline.com
Senti Biosciences: Understanding the Market Moves - StocksToTrade
Chardan Raises Price Target on Senti Biosciences to $13 From $12, Keeps Buy Rating - marketscreener.com
Check Out Senti Biosciences Inc (SNTI)’s Trade Data Rather Than the Analysts’ Views - Setenews
Senti Bio’s SENTI-202 shows promising results in AML clinical trial By Investing.com - Investing.com Australia
Biotech Stocks Today: FDA Shifts, ASH 2025 Winners and Market Close Recap (December 9, 2025) - ts2.tech
Unveiling Senti Biosciences: Shaping the Future of Cancer Therapy? - StocksToTrade
Senti Bio price target raised to $13 from $12 at Chardan - TipRanks
Why Is Gene Therapy Focused Senti Bio Stock Falling Today? - Benzinga
SNTI: SENTI-202 achieved 50% ORR and 42% CR/CRh with deep, durable remissions in R/R AML - TradingView — Track All Markets
Lyft Stock Soars Following Strategic Euro Expansion Through FreeNow Acquisition - StocksToTrade
“Smart” NK Cells: Senti Bio’s Logic-Gated Immunotherapy Strikes R/R AML - Inside Precision Medicine
Senti Biosciences’ Strategic Moves Ripple Across Biotech Market - timothysykes.com
Senti Biosciences Secures FDA RMAT Designation For SENTI-202 - Nasdaq
Senti Biosciences Announces Positive Data From Ongoing SENTI-202 Trial, Stock Up - Nasdaq
Senti Announced Positive Phase 1 Data For SENTI-202 In Relapsed/ Refractory AML - Nasdaq
Senti Biosciences’ Surge: Buy or Wait? - timothysykes.com
Senti Biosciences Reports Promising Phase 1 Trial Results - TipRanks
Senti Bio’s SENTI-202 shows promising results in AML clinical trial - Investing.com
Senti Bio stock soars after positive cancer therapy trial results By Investing.com - Investing.com Canada
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile - The Manila Times
Senti Biosciences, Inc. Announces Initial Clinical Data for SENTI-202 - TradingView — Track All Markets
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia - marketscreener.com
Is Senti Biosciences Inc a good long term investmentLong-Term Investment Plans & Small Investment Growth Plans - earlytimes.in
Finanzdaten der Senti Biosciences Inc-Aktie (SNTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Senti Biosciences Inc-Aktie (SNTI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lu Timothy K | CEO |
Feb 06 '25 |
Sale |
4.36 |
545 |
2,376 |
82,082 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 04 '25 |
Sale |
4.07 |
1,297 |
5,279 |
8,803 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 06 '25 |
Sale |
4.37 |
182 |
795 |
8,621 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):